These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 18705999)

  • 1. Calculation of sample size for stroke trials assessing functional outcome: comparison of binary and ordinal approaches.
    Optimising Analysis of Stroke Trials Collaboration
    Int J Stroke; 2008 May; 3(2):78-84. PubMed ID: 18705999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calculation of numbers-needed-to-treat in parallel group trials assessing ordinal outcomes: case examples from acute stroke and stroke prevention.
    ; Bath P; Hogg C; Tracy M; Pocock S
    Int J Stroke; 2011 Dec; 6(6):472-9. PubMed ID: 21645271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size calculation in survival trials accounting for time-varying relationship between noncompliance and risk of outcome event.
    Li B; Grambsch P
    Clin Trials; 2006; 3(4):349-59. PubMed ID: 17060209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimates, power and sample size calculations for two-sample ordinal outcomes under before-after study designs.
    Strickland PA; Lu SE
    Stat Med; 2003 Jun; 22(11):1807-18. PubMed ID: 12754716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of continuous versus dichotomous outcome variables on study power when sample sizes of orthopaedic randomized trials are small.
    Bhandari M; Lochner H; Tornetta P
    Arch Orthop Trauma Surg; 2002 Mar; 122(2):96-8. PubMed ID: 11880910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample size calculations in scleroderma: a rational approach to choosing outcome measurements in scleroderma trials.
    Pope JE; Bellamy N
    Clin Invest Med; 1995 Feb; 18(1):1-10. PubMed ID: 7768060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size calculations for population pharmacodynamic experiments involving repeated dichotomous observations.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2008; 18(6):1212-27. PubMed ID: 18991118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample-size calculations for studies with correlated ordinal outcomes.
    Kim HY; Williamson JM; Lyles CM
    Stat Med; 2005 Oct; 24(19):2977-87. PubMed ID: 16149125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An efficient test for the analysis of dichotomized variables when the reliability is known.
    Borm GF; Munneke M; Lemmers O; van Zuijlen M
    Stat Med; 2007 Aug; 26(18):3498-510. PubMed ID: 16981185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A general approach for sample size and statistical power calculations assessing of interventions using a mixture model in the presence of detection limits.
    Nie L; Chu H; Cole SR
    Contemp Clin Trials; 2006 Oct; 27(5):483-91. PubMed ID: 16769254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of bootstrap methods for estimating sample size and analysing health-related quality of life outcomes.
    Walters SJ; Campbell MJ
    Stat Med; 2005 Apr; 24(7):1075-102. PubMed ID: 15570625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consultants' forum: should post hoc sample size calculations be done?
    Walters SJ
    Pharm Stat; 2009; 8(2):163-9. PubMed ID: 18416448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian sample size calculations for a non-inferiority test of two proportions in clinical trials.
    Daimon T
    Contemp Clin Trials; 2008 Jul; 29(4):507-16. PubMed ID: 18201944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size calculation for the van Elteren test adjusting for ties.
    Zhao YD; Rahardja D; Mei Y
    J Biopharm Stat; 2008; 18(6):1112-9. PubMed ID: 18991111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robustness and power of analysis of covariance applied to ordinal scaled data as arising in randomized controlled trials.
    Sullivan LM; D'Agostino RB
    Stat Med; 2003 Apr; 22(8):1317-34. PubMed ID: 12687657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A small p-value from an observed data is not evidence of adequate power for future similar-sized studies: a cautionary note.
    Atenafu EG; Hamid JS; Stephens D; To T; Beyene J
    Contemp Clin Trials; 2009 Mar; 30(2):155-7. PubMed ID: 19063996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stopping clinical trials early for benefit: impact on estimation.
    Freidlin B; Korn EL
    Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size calculation for the Power Model for dose proportionality studies.
    Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
    Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.
    Leon AC
    J Clin Psychiatry; 2004 Nov; 65(11):1511-4. PubMed ID: 15554764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The methods for handling missing data in clinical trials influence sample size requirements.
    Auleley GR; Giraudeau B; Baron G; Maillefert JF; Dougados M; Ravaud P
    J Clin Epidemiol; 2004 May; 57(5):447-53. PubMed ID: 15196614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.